Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel

The Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test contains 1 test with 12 biomarkers.

Brief Description: The Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test is a set of laboratory analyses designed to aid in the diagnosis and monitoring of systemic lupus erythematosus, commonly known as lupus. Lupus is a complex autoimmune disease that can affect various organs and tissues in the body.

Collection Method: Blood Draw

Specimen Type: Serum

Test Preparation: No preparation required

If ANA Screen, IFA is positive, then ANA Titer and Pattern will be performed at an additional charge - $24.95

When and Why the Test May Be Ordered:

This comprehensive panel is ordered when a patient presents with symptoms suggestive of lupus, such as joint pain, fatigue, skin rashes, fever, and unexplained weight loss. It's also used for patients with known lupus to monitor disease activity and response to treatment.

What the Test Checks For:

The SLE Comprehensive Diagnostic Panel test checks for various antibodies and biomarkers associated with lupus. These include:

• ANA Screen, IFA, with Reflex to Titer and Pattern
• DNA (ds) Antibody
• Sjogren's Antibodies (SS-A, SS-B)
• Sm Antibody
• RNP Antibody 
• Chromatin (Nucleosomal) Antibody
• Complement Component C3c and C4c
• Complement, Total (CH50)

Other Lab Tests That May Be Ordered Alongside:

When an SLE Comprehensive Diagnostic Panel is ordered, it's often part of a broader evaluation of the disease's activity, organ involvement, and differential diagnosis. Here are some tests commonly ordered alongside it:

1. Complete Blood Count (CBC) with Differential:

   • Purpose: To evaluate overall blood health, including red and white blood cells, and platelets.
   • Why Is It Ordered: To assess for signs of anemia, leukopenia, or thrombocytopenia, which are common in SLE.

2. Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP):

   • Purpose: To measure markers of inflammation.
   • Why Is It Ordered: To evaluate the level of systemic inflammation, which is often present in SLE.

3. Complement Components (C3, C4, CH50):

   • Purpose: To measure levels of complement proteins.
   • Why Is It Ordered: Low complement levels can be indicative of SLE activity, as these proteins are consumed during active disease.

4. Kidney Function Test:

   • Purpose: To assess kidney function and look for proteinuria or hematuria.
   • Why Is It Ordered: To monitor for lupus nephritis, a common and serious complication of SLE.

5. Liver Function Test:

   • Purpose: To assess liver health.
   • Why Is It Ordered: To evaluate for liver involvement, which can occur in SLE.

6. Anti-Phospholipid Antibodies (including Anti-Cardiolipin Antibodies, Lupus Anticoagulant, and Beta-2 Glycoprotein I Antibodies):

   • Purpose: To detect antibodies associated with antiphospholipid syndrome (APS).
   • Why Is It Ordered: To assess for APS, which can coexist with SLE and is important to diagnose due to its association with blood clots.

These tests, when ordered alongside an SLE Comprehensive Diagnostic Panel, provide a broad overview of the patient’s health status in the context of SLE. They are crucial for confirming the diagnosis, assessing disease activity and organ involvement, and monitoring the effects of treatment. The specific combination of tests will depend on the individual’s symptoms, clinical presentation, and history.

Conditions or Diseases Requiring the Test:

Systemic lupus erythematosus (SLE) is the primary condition that would necessitate this comprehensive panel. Lupus is a chronic autoimmune disease that can affect multiple organs, including joints, skin, kidneys, heart, lungs, and brain.

How Health Care Providers Use the Results:

• Diagnosis: A positive combination of these markers can confirm the presence of lupus.
• Disease Activity Assessment: Regular testing can help monitor disease activity and guide treatment decisions.
• Treatment Monitoring: Monitoring changes in biomarker levels can indicate treatment effectiveness or the need for adjustments.
• Organ Involvement: Results can indicate potential organ involvement, such as kidney or heart complications.

In conclusion, the SLE Comprehensive Diagnostic Panel test is a powerful tool for diagnosing and monitoring systemic lupus erythematosus. By assessing a range of biomarkers and antibodies associated with the disease, healthcare providers can make informed decisions about patient care and management strategies.

Most Common Questions About the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test:

Clinical Utility and Interpretation

What is the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test, and why is it important?

The SLE Comprehensive Diagnostic Panel test is a combination of blood tests designed to diagnose and monitor Systemic Lupus Erythematosus, an autoimmune disease where the body's immune system mistakenly attacks healthy tissue. This panel aids in detecting specific antibodies and other markers that are frequently seen in individuals with SLE, facilitating an accurate diagnosis and providing a comprehensive overview of the patient's condition.

How are the results of the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test interpreted?

Results of the SLE Comprehensive Diagnostic Panel are interpreted based on the presence and levels of certain antibodies and other markers. Elevated levels of antibodies such as antinuclear antibody (ANA), anti-dsDNA, and anti-Smith, among others, suggest a likelihood of SLE. However, the diagnosis of SLE is based on a combination of clinical and laboratory criteria, so these results are integrated with clinical findings for a conclusive diagnosis.

Clinical Applications and Diagnoses

In which scenarios is the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test typically ordered?

The SLE Diagnostic Panel is usually ordered when a patient presents with symptoms suggestive of SLE such as joint pain, skin rash, fatigue, and kidney dysfunction. It is particularly valuable in differentiating SLE from other autoimmune or inflammatory disorders that may have overlapping symptoms.

How does the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test assist in treatment decisions?

By providing a detailed picture of the immune activity and specific markers related to SLE, the test aids physicians in tailoring treatments specific to the patient's needs. For instance, elevated levels of certain markers may suggest more aggressive disease requiring more intensive treatment.

Comparative Insights

How does the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test compare to individual tests for SLE?

The comprehensive panel offers a holistic view of the patient's immune response and the activity of SLE. While individual tests might provide insights into specific aspects of the disease, the panel can be more cost-effective and efficient in offering a broader understanding, especially when diagnosing or when the clinical picture is unclear.

Understanding Limitations and Challenges

What are some of the limitations of the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test?

While the comprehensive panel provides a lot of information, it may not always offer a clear-cut diagnosis. SLE is a complex disease with variable presentation, and no single test or panel can diagnose it definitively. Clinical judgment and correlation with physical findings and patient history are crucial. Additionally, false-positive or false-negative results can occur, particularly in early or mild cases of the disease.

Can the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test distinguish between active and inactive disease states?

Certain markers in the panel, such as complement levels or anti-dsDNA antibodies, can provide insights into disease activity. Elevated anti-dsDNA levels and decreased complement levels often correlate with disease flares. However, regular monitoring and clinical correlation are essential, as laboratory values may not always match the clinical picture.

Additional Questions and Insights

If a patient's Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test results are negative, but clinical suspicion remains high, what should be the next step?

If the test results are negative but the clinical suspicion for SLE remains high, the physician may consider repeating the tests after some time or might look into other specific tests or markers. Monitoring the patient's symptoms and progression is crucial, as the disease may evolve, and lab findings might become more apparent over time.

How do other conditions or autoimmune diseases impact the results of the Systemic Lupus Erythematosus (SLE) Comprehensive Diagnostic Panel test?

Other autoimmune diseases can produce similar antibodies, which might lead to positive results on the panel. For example, the presence of ANA is not exclusive to SLE and can be seen in other conditions like Sjogren's syndrome, scleroderma, or rheumatoid arthritis. This underscores the importance of integrating lab results with clinical findings for an accurate diagnosis.

We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.